Nestle has announced today (26 May) that its Gerber Products division has been granted the first ever Food and Drink Administration (FDA) qualified health claim for its Gerber Good Start infant formula range.

The company said that the FDA concluded that current scientific evidence is appropriate for the consideration of a qualified health claim relating to a reduced risk of atopic dermatitis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Nestle, atopic dermatitis is the most common type of allergic disease in infancy, and develops in nearly one in five babies.

The FDA said that for healthy infants who are not exclusively breastfed and who have a family history of allergy, “feeding a 100% whey protein partially hydrolyzed infant formula from birth up to 4 months of age instead of a formula containing intact cow’s milk proteins may reduce the risk of developing atopic dermatitis throughout the first year of life”.

It said that partially hydrolyzed formulas should not be fed to infants who are allergic to milk or to infants with existing milk allergy symptoms.